TY - JOUR AU - Buss, N. A. AU - Henderson, S. J. AU - Mcfarlane, M. AU - Shenton, J. M. AU - Haan, L. D. PY - 2012 DA - 2012// TI - Monoclonal antibody therapeutics: history and future JO - Curr Opin Pharmacol VL - 12 UR - https://doi.org/10.1016/j.coph.2012.08.001 DO - 10.1016/j.coph.2012.08.001 ID - Buss2012 ER - TY - JOUR AU - Kolk, L. E. V. D. AU - Grillo-Lopez, A. J. AU - Baars, J. W. AU - Hack, C. E. AU - Oers, M. H. J. V. PY - 2001 DA - 2001// TI - Complement activation plays a key role in the side-effects of rituximab treatment JO - Br J Haematol VL - 115 UR - https://doi.org/10.1046/j.1365-2141.2001.03166.x DO - 10.1046/j.1365-2141.2001.03166.x ID - Kolk2001 ER - TY - JOUR AU - Isabwe, G. A. C. AU - Neuer, M. G. AU - Sanchez, L. D. L. V. AU - Lynch, D. -. M. AU - Marquis, K. AU - Castells, M. PY - 2018 DA - 2018// TI - Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes JO - J Allergy Clin Immunol. VL - 142 UR - https://doi.org/10.1016/j.jaci.2018.02.018 DO - 10.1016/j.jaci.2018.02.018 ID - Isabwe2018 ER - TY - JOUR AU - Ornust, S. V. AU - Lamb, H. M. AU - Barman Balfour, J. A. PY - 1999 DA - 1999// TI - Rituximab JO - Drugs. VL - 58 UR - https://doi.org/10.2165/00003495-199958010-00009 DO - 10.2165/00003495-199958010-00009 ID - Ornust1999 ER - TY - JOUR AU - Bugelski, P. J. AU - Achuthanandam, R. AU - Capocasale, R. J. AU - Treacy, G. AU - Bouman-Thio, E. PY - 2009 DA - 2009// TI - Monoclonal antibody-induced cytokine-release syndrome JO - Expert Rev Clin Immunol. VL - 5 UR - https://doi.org/10.1586/eci.09.31 DO - 10.1586/eci.09.31 ID - Bugelski2009 ER - TY - JOUR AU - Kimby, E. PY - 2005 DA - 2005// TI - Tolerability and safety of rituximab (MabThera®) JO - Cancer Treat Rev VL - 31 UR - https://doi.org/10.1016/j.ctrv.2005.05.007 DO - 10.1016/j.ctrv.2005.05.007 ID - Kimby2005 ER - TY - JOUR AU - Ng, C. M. AU - Bruno, R. AU - Combs, D. AU - Davies, B. PY - 2005 DA - 2005// TI - Population pharmacokinetics of rituximab (Anti-CD20 Monoclonal Antibody) in rheumatoid arthritis patients during a phase II clinical trial JO - J Clin Pharmacol. VL - 45 UR - https://doi.org/10.1177/0091270005277075 DO - 10.1177/0091270005277075 ID - Ng2005 ER - TY - JOUR AU - Valent, P. AU - Bonadonna, P. AU - Hartmann, K. AU - Broesby-Olsen, S. AU - Brockow, K. AU - Butterfield, J. H. PY - 2019 DA - 2019// TI - Why the 20% 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome JO - Int Arch Allergy Immunol VL - 180 UR - https://doi.org/10.1159/000501079 DO - 10.1159/000501079 ID - Valent2019 ER - TY - JOUR AU - Maneiro, J. R. AU - Salgado, E. AU - Gomez-Reino, J. J. PY - 2013 DA - 2013// TI - Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions JO - Clin Gov Int J VL - 173 ID - Maneiro2013 ER - TY - JOUR AU - Salomon-Perzyński, A. AU - Końska, A. AU - Zawirska, D. AU - Lech-Marańda, E. AU - Jamroziak, K. PY - 2018 DA - 2018// TI - Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab–associated anaphylaxis JO - Polish Archiv Intern Med. VL - 128 UR - https://doi.org/10.20452/pamw.4327 DO - 10.20452/pamw.4327 ID - Salomon-Perzyński2018 ER -